{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:24:37Z","timestamp":1794255877806,"version":"4.9.0"},"reference-count":117,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Liaoning Provincial Science and Technology Plan Joint Plan","award":["2024JH2\/102600285"],"award-info":[{"award-number":["2024JH2\/102600285"]}]},{"name":"Independent Research Funding of General Hospital of Northern Theater Command","award":["ZZKY2024018"],"award-info":[{"award-number":["ZZKY2024018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12325-026-03696-z","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T06:41:03Z","timestamp":1785912063000},"page":"5084-5108","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Relevance of Bile Acid and Bile Acid-Related Therapy in Liver Cirrhosis: A Review"],"prefix":"10.1007","volume":"43","author":[{"given":"Guangwen","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxiu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahum","family":"M\u00e9ndez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9448-6739","authenticated-orcid":false,"given":"Xingshun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"issue":"6","key":"3696_CR1","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","volume":"20","author":"DQ Huang","year":"2023","unstructured":"Huang DQ, Terrault NA, et al. Global epidemiology of cirrhosis - aetiology, trends and predictions. Nat Rev Gastroenterol Hepatol. 2023;20(6):388\u201398.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"3696_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, et al. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516\u201337.","journal-title":"J Hepatol"},{"key":"3696_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108238","volume":"237","author":"J Cai","year":"2022","unstructured":"Cai J, Rimal B, et al. Bile acid metabolism and signaling, the microbiota, and metabolic disease. Pharmacol Ther. 2022;237:108238.","journal-title":"Pharmacol Ther"},{"key":"3696_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12070647","author":"H Mori","year":"2022","unstructured":"Mori H, Svegliati Baroni G, et al. Farnesoid X receptor, bile acid metabolism, and gut microbiota. Metabolites. 2022. https:\/\/doi.org\/10.3390\/metabo12070647.","journal-title":"Metabolites"},{"issue":"4","key":"3696_CR5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41579-022-00805-x","volume":"21","author":"SL Collins","year":"2023","unstructured":"Collins SL, Stine JG, et al. Bile acids and the gut microbiota: metabolic interactions and impacts on disease. Nat Rev Microbiol. 2023;21(4):236\u201347.","journal-title":"Nat Rev Microbiol"},{"issue":"1","key":"3696_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.jhep.2024.09.032","volume":"82","author":"CD Fuchs","year":"2025","unstructured":"Fuchs CD, Simbrunner B, et al. Bile acid metabolism and signalling in liver disease. J Hepatol. 2025;82(1):134\u201353.","journal-title":"J Hepatol"},{"issue":"5","key":"3696_CR7","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1021\/acs.jproteome.0c00852","volume":"20","author":"C Sang","year":"2021","unstructured":"Sang C, Wang X, et al. Bile acid profiles are distinct among patients with different etiologies of chronic liver disease. J Proteome Res. 2021;20(5):2340\u201351.","journal-title":"J Proteome Res"},{"issue":"5","key":"3696_CR8","first-page":"4058","volume":"18","author":"N Liu","year":"2019","unstructured":"Liu N, Feng J, et al. Role of bile acids in the diagnosis and progression of liver cirrhosis: a prospective observational study. Exp Ther Med. 2019;18(5):4058\u201366.","journal-title":"Exp Ther Med"},{"issue":"4","key":"3696_CR9","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1055\/s-0036-1593881","volume":"36","author":"J Lachar","year":"2016","unstructured":"Lachar J, Bajaj JS. Changes in the microbiome in cirrhosis and relationship to complications: hepatic encephalopathy, spontaneous bacterial peritonitis, and sepsis. Semin Liver Dis. 2016;36(4):327\u201330.","journal-title":"Semin Liver Dis"},{"issue":"15","key":"3696_CR10","doi-asserted-by":"publisher","first-page":"12123","DOI":"10.3390\/ijms241512123","volume":"24","author":"C Yin","year":"2023","unstructured":"Yin C, Zhong R, et al. The potential of bile acids as biomarkers for metabolic disorders. Int J Mol Sci. 2023;24(15):12123.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"3696_CR11","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41575-021-00566-7","volume":"19","author":"CD Fuchs","year":"2022","unstructured":"Fuchs CD, Trauner M. Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology. Nat Rev Gastroenterol Hepatol. 2022;19(7):432\u201350.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"3696_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193824","volume":"13","author":"L Luo","year":"2018","unstructured":"Luo L, Aubrecht J, et al. Assessment of serum bile acid profiles as biomarkers of liver injury and liver disease in humans. PLoS ONE. 2018;13(3):e0193824.","journal-title":"PLoS ONE"},{"key":"3696_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/754067","volume":"2012","author":"T Li","year":"2012","unstructured":"Li T, Chiang JY. Bile acid signaling in liver metabolism and diseases. J Lipids. 2012;2012:754067.","journal-title":"J Lipids"},{"issue":"1","key":"3696_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00253-016-8006-6","volume":"101","author":"C Staley","year":"2017","unstructured":"Staley C, Weingarden AR, et al. Interaction of gut microbiota with bile acid metabolism and its influence on disease states. Appl Microbiol Biotechnol. 2017;101(1):47\u201364.","journal-title":"Appl Microbiol Biotechnol"},{"issue":"5","key":"3696_CR15","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","volume":"17","author":"TQ de Aguiar Vallim","year":"2013","unstructured":"de Aguiar Vallim TQ, Tarling EJ, et al. Pleiotropic roles of bile acids in metabolism. Cell Metab. 2013;17(5):657\u201369.","journal-title":"Cell Metab"},{"key":"3696_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2022.111618","volume":"548","author":"JYL Chiang","year":"2022","unstructured":"Chiang JYL, Ferrell JM. Discovery of farnesoid X receptor and its role in bile acid metabolism. Mol Cell Endocrinol. 2022;548:111618.","journal-title":"Mol Cell Endocrinol"},{"issue":"10","key":"3696_CR17","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1111\/apt.16602","volume":"54","author":"B Simbrunner","year":"2021","unstructured":"Simbrunner B, Trauner M, et al. Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. Aliment Pharmacol Ther. 2021;54(10):1243\u201362.","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"3696_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24279","volume":"36","author":"Y Shen","year":"2022","unstructured":"Shen Y, Liu K, et al. A simple and reliable bile acid assay in human serum by LC-MS\/MS. J Clin Lab Anal. 2022;36(3):e24279.","journal-title":"J Clin Lab Anal"},{"key":"3696_CR19","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/978-1-61737-985-7_6","volume":"708","author":"M Hagio","year":"2011","unstructured":"Hagio M, Matsumoto M, et al. Bile acid analysis in various biological samples using ultra performance liquid chromatography\/electrospray ionization-mass spectrometry (UPLC\/ESI-MS). Methods Mol Biol. 2011;708:119\u201329.","journal-title":"Methods Mol Biol"},{"issue":"1","key":"3696_CR20","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s12944-018-0774-9","volume":"17","author":"Y Liu","year":"2018","unstructured":"Liu Y, Rong Z, et al. Detection technologies and metabolic profiling of bile acids: a comprehensive review. Lipids Health Dis. 2018;17(1):121.","journal-title":"Lipids Health Dis"},{"issue":"5","key":"3696_CR21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1515\/cclm-2019-0354","volume":"58","author":"X Fu","year":"2020","unstructured":"Fu X, Xiao Y, et al. Serum bile acids profiling by liquid chromatography-tandem mass spectrometry (LC-MS\/MS) and its application on pediatric liver and intestinal diseases. Clin Chem Lab Med. 2020;58(5):787\u201397.","journal-title":"Clin Chem Lab Med"},{"key":"3696_CR22","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cca.2016.11.014","volume":"464","author":"B Amplatz","year":"2017","unstructured":"Amplatz B, Z\u00f6hrer E, et al. Bile acid preparation and comprehensive analysis by high performance liquid chromatography-high-resolution mass spectrometry. Clin Chim Acta. 2017;464:85\u201392.","journal-title":"Clin Chim Acta"},{"issue":"6","key":"3696_CR23","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1016\/S1473-3099(24)00307-4","volume":"24","author":"T Burki","year":"2024","unstructured":"Burki T. WHO\u2019s 2024 global hepatitis report. Lancet Infect Dis. 2024;24(6):e362\u20133.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"3696_CR24","doi-asserted-by":"publisher","first-page":"230","DOI":"10.2471\/BLT.18.219469","volume":"97","author":"J Liu","year":"2019","unstructured":"Liu J, Liang W, et al. Countdown to 2030: eliminating hepatitis B disease. China Bull World Health Organ. 2019;97(3):230\u20138.","journal-title":"China Bull World Health Organ"},{"issue":"4","key":"3696_CR25","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1111\/jcmm.14951","volume":"24","author":"X Wang","year":"2020","unstructured":"Wang X, Chen L, et al. Modulation of bile acid profile by gut microbiota in chronic hepatitis B. J Cell Mol Med. 2020;24(4):2573\u201381.","journal-title":"J Cell Mol Med"},{"issue":"4","key":"3696_CR26","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1021\/acs.jproteome.5b00217","volume":"15","author":"X Wang","year":"2016","unstructured":"Wang X, Xie G, et al. Serum bile acids are associated with pathological progression of hepatitis b-induced cirrhosis. J Proteome Res. 2016;15(4):1126\u201334.","journal-title":"J Proteome Res"},{"issue":"8","key":"3696_CR27","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000019248","volume":"99","author":"LT Yan","year":"2020","unstructured":"Yan LT, Wang LL, et al. Total bile acid-to-cholesterol ratio as a novel noninvasive marker for significant liver fibrosis and cirrhosis in patients with non-cholestatic chronic hepatitis B virus infection. Medicine (Baltimore). 2020;99(8):e19248.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"3696_CR28","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1111\/liv.15041","volume":"42","author":"T Inoue","year":"2022","unstructured":"Inoue T, Funatsu Y, et al. Bile acid dysmetabolism in the gut-microbiota-liver axis under hepatitis C virus infection. Liver Int. 2022;42(1):124\u201334.","journal-title":"Liver Int"},{"key":"3696_CR29","doi-asserted-by":"publisher","first-page":"10191","DOI":"10.3389\/bjbs.2021.10191","volume":"79","author":"A Khalil","year":"2022","unstructured":"Khalil A, ElSheashaey A, et al. Value of bile acids in diagnosing hepatitis C virus-induced liver cirrhosis and hepatocellular carcinoma. Br J Biomed Sci. 2022;79:10191.","journal-title":"Br J Biomed Sci"},{"issue":"2","key":"3696_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1365-2893.2012.01628.x","volume":"20","author":"A Shlomai","year":"2013","unstructured":"Shlomai A, Halfon P, et al. Serum bile acid levels as a predictor for the severity of liver fibrosis in patients with chronic hepatitis C. J Viral Hepat. 2013;20(2):95\u2013102.","journal-title":"J Viral Hepat"},{"issue":"6","key":"3696_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.medcli.2017.12.021","volume":"151","author":"A Pares","year":"2018","unstructured":"Pares A. Primary biliary cholangitis. Med Clin (Barc). 2018;151(6):242\u20139.","journal-title":"Med Clin (Barc)"},{"issue":"10139","key":"3696_CR32","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","volume":"391","author":"JK Dyson","year":"2018","unstructured":"Dyson JK, Beuers U, et al. Primary sclerosing cholangitis. Lancet. 2018;391(10139):2547\u201359.","journal-title":"Lancet"},{"issue":"3","key":"3696_CR33","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1159\/000452300","volume":"94","author":"H Yang","year":"2016","unstructured":"Yang H, Duan Z. Bile acids and the potential role in primary biliary cirrhosis. Digestion. 2016;94(3):145\u201353.","journal-title":"Digestion"},{"issue":"9","key":"3696_CR34","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.autrev.2017.07.002","volume":"16","author":"Y Li","year":"2017","unstructured":"Li Y, Tang R, et al. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev. 2017;16(9):885\u201396.","journal-title":"Autoimmun Rev"},{"issue":"4","key":"3696_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.dld.2011.10.025","volume":"44","author":"J Trottier","year":"2012","unstructured":"Trottier J, Bialek A, et al. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Dig Liver Dis. 2012;44(4):303\u201310.","journal-title":"Dig Liver Dis"},{"issue":"3","key":"3696_CR36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1136\/gut.13.3.201","volume":"13","author":"GM Murphy","year":"1972","unstructured":"Murphy GM, Ross A, et al. Serum bile acids in primary biliary cirrhosis. Gut. 1972;13(3):201\u20136.","journal-title":"Gut"},{"issue":"1","key":"3696_CR37","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s12016-019-08731-2","volume":"58","author":"W Chen","year":"2020","unstructured":"Chen W, Wei Y, et al. Comprehensive analysis of serum and fecal bile acid profiles and interaction with gut microbiota in primary biliary cholangitis. Clin Rev Allergy Immunol. 2020;58(1):25\u201338.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"3696_CR38","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/hep.31652","volume":"74","author":"OY Mousa","year":"2021","unstructured":"Mousa OY, Juran BD, et al. Bile acid profiles in primary sclerosing cholangitis and their ability to predict hepatic decompensation. Hepatology. 2021;74(1):281\u201395.","journal-title":"Hepatology"},{"issue":"4","key":"3696_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1093\/alcalc\/agz036","volume":"54","author":"N Hosseini","year":"2019","unstructured":"Hosseini N, Shor J, et al. Alcoholic hepatitis: a review. Alcohol Alcohol. 2019;54(4):408\u201316.","journal-title":"Alcohol Alcohol"},{"issue":"9","key":"3696_CR40","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/apt.14949","volume":"48","author":"D Ciocan","year":"2018","unstructured":"Ciocan D, Voican CS, et al. Bile acid homeostasis and intestinal dysbiosis in alcoholic hepatitis. Aliment Pharmacol Ther. 2018;48(9):961\u201374.","journal-title":"Aliment Pharmacol Ther"},{"issue":"11","key":"3696_CR41","doi-asserted-by":"publisher","first-page":"G929","DOI":"10.1152\/ajpgi.00315.2013","volume":"306","author":"G Kakiyama","year":"2014","unstructured":"Kakiyama G, Hylemon PB, et al. Colonic inflammation and secondary bile acids in alcoholic cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2014;306(11):G929\u201337.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"2","key":"3696_CR42","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S0168-8278(05)80401-5","volume":"21","author":"JC Trinchet","year":"1994","unstructured":"Trinchet JC, Gerhardt MF, et al. Serum bile acids and cholestasis in alcoholic hepatitis. Relationship with usual liver tests and histological features. J Hepatol. 1994;21(2):235\u201340.","journal-title":"J Hepatol"},{"issue":"2","key":"3696_CR43","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jhep.2018.03.031","volume":"69","author":"K Brandl","year":"2018","unstructured":"Brandl K, Hartmann P, et al. Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. J Hepatol. 2018;69(2):396\u2013405.","journal-title":"J Hepatol"},{"issue":"2\u20133","key":"3696_CR44","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/0009-8981(84)90293-6","volume":"136","author":"B Joelsson","year":"1984","unstructured":"Joelsson B, Hultberg B, et al. Total fasting serum bile acids and beta-hexosaminidase in alcoholic liver disease. Clin Chim Acta. 1984;136(2\u20133):203\u20139.","journal-title":"Clin Chim Acta"},{"issue":"10","key":"3696_CR45","doi-asserted-by":"publisher","first-page":"110940","DOI":"10.1016\/j.isci.2024.110940","volume":"27","author":"D Paudel","year":"2024","unstructured":"Paudel D, Hao F, et al. Elevated systemic total bile acids escalate susceptibility to alcohol-associated liver disease. iScience. 2024;27(10):110940.","journal-title":"iScience"},{"issue":"9","key":"3696_CR46","doi-asserted-by":"publisher","first-page":"ITC65","DOI":"10.7326\/AITC201811060","volume":"169","author":"XJ Wang","year":"2018","unstructured":"Wang XJ, Malhi H. Nonalcoholic fatty liver disease. Ann Intern Med. 2018;169(9):ITC65\u201380.","journal-title":"Ann Intern Med"},{"issue":"11","key":"3696_CR47","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","volume":"60","author":"BC Ferslew","year":"2015","unstructured":"Ferslew BC, Xie G, et al. Altered bile acid metabolome in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2015;60(11):3318\u201328.","journal-title":"Dig Dis Sci"},{"issue":"4","key":"3696_CR48","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S1665-2681(19)31170-6","volume":"14","author":"NE Aguilar-Olivos","year":"2015","unstructured":"Aguilar-Olivos NE, Carrillo-C\u00f3rdova D, et al. The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. Ann Hepatol. 2015;14(4):487\u201393.","journal-title":"Ann Hepatol"},{"issue":"44","key":"3696_CR49","doi-asserted-by":"publisher","first-page":"16452","DOI":"10.3748\/wjg.v20.i44.16452","volume":"20","author":"N Arslan","year":"2014","unstructured":"Arslan N. Obesity, fatty liver disease and intestinal microbiota. World J Gastroenterol. 2014;20(44):16452\u201363.","journal-title":"World J Gastroenterol"},{"key":"3696_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2025.118182","volume":"188","author":"M Zhao","year":"2025","unstructured":"Zhao M, Zhao J, et al. The bile acid-gut microbiota axis: a central hub for physiological regulation and a novel therapeutic target for metabolic diseases. Biomed Pharmacother. 2025;188:118182.","journal-title":"Biomed Pharmacother"},{"key":"3696_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/antiox13111386","author":"E Scarpellini","year":"2024","unstructured":"Scarpellini E, Scarcella M, et al. Gut microbiota and metabolic dysfunction-associated steatotic liver disease. Antioxidants. 2024. https:\/\/doi.org\/10.3390\/antiox13111386.","journal-title":"Antioxidants"},{"issue":"2","key":"3696_CR52","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1002\/hep.29359","volume":"67","author":"P Puri","year":"2018","unstructured":"Puri P, Daita K, et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology. 2018;67(2):534\u201348.","journal-title":"Hepatology"},{"issue":"1","key":"3696_CR53","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/MPG.0000000000000774","volume":"61","author":"J Jahnel","year":"2015","unstructured":"Jahnel J, Zohrer E, et al. Serum bile acid levels in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2015;61(1):85\u201390.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"3696_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151829","volume":"11","author":"M Mouzaki","year":"2016","unstructured":"Mouzaki M, Wang AY, et al. Bile acids and dysbiosis in non-alcoholic fatty liver disease. PLoS ONE. 2016;11(5):e0151829.","journal-title":"PLoS ONE"},{"key":"3696_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/nu16020250","author":"J Fitzinger","year":"2024","unstructured":"Fitzinger J, Rodriguez-Blanco G, et al. Gender-specific bile acid profiles in non-alcoholic fatty liver disease. Nutrients. 2024. https:\/\/doi.org\/10.3390\/nu16020250.","journal-title":"Nutrients"},{"issue":"1","key":"3696_CR56","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s12943-024-02101-z","volume":"23","author":"YT Chan","year":"2024","unstructured":"Chan YT, Zhang C, et al. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma. Mol Cancer. 2024;23(1):189.","journal-title":"Mol Cancer"},{"issue":"9160","key":"3696_CR57","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/S0140-6736(98)09148-X","volume":"353","author":"DF Schafer","year":"1999","unstructured":"Schafer DF, Sorrell MF. Hepatocellular carcinoma. Lancet. 1999;353(9160):1253\u20137.","journal-title":"Lancet"},{"issue":"9","key":"3696_CR58","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1038\/s41423-023-01026-9","volume":"20","author":"Z Xun","year":"2023","unstructured":"Xun Z, Yao X, et al. Emerging roles of bile acids in chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Cell Mol Immunol. 2023;20(9):1087\u20139.","journal-title":"Cell Mol Immunol"},{"key":"3696_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/srep38180","author":"H Wang","year":"2016","unstructured":"Wang H, Shang X, et al. Increased hepatocellular carcinoma risk in chronic hepatitis B patients with persistently elevated serum total bile acid: a retrospective cohort study. Sci Rep. 2016. https:\/\/doi.org\/10.1038\/srep38180.","journal-title":"Sci Rep"},{"issue":"3","key":"3696_CR60","doi-asserted-by":"publisher","first-page":"453","DOI":"10.5604\/16652681.1198826","volume":"15","author":"A Altamirano-Barrera","year":"2016","unstructured":"Altamirano-Barrera A, Uribe M, et al. Bile acids and the risk for hepatocellular carcinoma in primary biliary cholangitis. Ann Hepatol. 2016;15(3):453\u20134.","journal-title":"Ann Hepatol"},{"key":"3696_CR61","first-page":"5","volume":"6","author":"N M\u00e9ndez-S\u00e1nchez","year":"2020","unstructured":"M\u00e9ndez-S\u00e1nchez N, Valencia-Rodriguez A, et al. The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer. Hepatoma Res. 2020;6:5.","journal-title":"Hepatoma Res"},{"issue":"11","key":"3696_CR62","doi-asserted-by":"publisher","first-page":"e0545","DOI":"10.1097\/HC9.0000000000000545","volume":"8","author":"HB El-Serag","year":"2024","unstructured":"El-Serag HB, Thrift AP, et al. Serum levels of total bile acids are associated with an increased risk of HCC in patients with cirrhosis. Hepatol Commun. 2024;8(11):e0545.","journal-title":"Hepatol Commun"},{"issue":"9","key":"3696_CR63","doi-asserted-by":"publisher","first-page":"e0217","DOI":"10.1097\/HC9.0000000000000217","volume":"7","author":"W Chen","year":"2023","unstructured":"Chen W, Ding M, et al. Bile acids promote the development of HCC by activating the inflammasome. Hepatol Commun. 2023;7(9):e0217.","journal-title":"Hepatol Commun"},{"issue":"3","key":"3696_CR64","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3350\/cmh.2022.0103","volume":"29","author":"VK Br","year":"2023","unstructured":"Br VK, Sarin SK. Acute-on-chronic liver failure: terminology, mechanisms and management. Clin Mol Hepatol. 2023;29(3):670\u201389.","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"3696_CR65","doi-asserted-by":"publisher","first-page":"225","DOI":"10.14309\/ajg.0000000000001595","volume":"117","author":"JS Bajaj","year":"2022","unstructured":"Bajaj JS, O\u2019Leary JG, et al. Acute-on-chronic liver failure clinical guidelines. Am J Gastroenterol. 2022;117(2):225\u201352.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"3696_CR66","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1007\/s12072-024-10712-3","volume":"18","author":"Y Zeng","year":"2024","unstructured":"Zeng Y, Gan D, et al. The impact of artificial liver support system on intestinal microbiota and serum bile acid profiles in patients with acute-on-chronic liver failure: a prospective cohort study. Hepatol Int. 2024;18(5):1540\u201354.","journal-title":"Hepatol Int"},{"issue":"2","key":"3696_CR67","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/liv.13201","volume":"37","author":"T Horvatits","year":"2017","unstructured":"Horvatits T, Drolz A, et al. Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis. Liver Int. 2017;37(2):224\u201331.","journal-title":"Liver Int"},{"key":"3696_CR68","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114004","volume":"198","author":"M Yu","year":"2021","unstructured":"Yu M, Zhou C, et al. Molecular classification and clinical diagnosis of acute-on-chronic liver failure patients by serum metabolomics. J Pharm Biomed Anal. 2021;198:114004.","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"3696_CR69","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.apsb.2016.09.003","volume":"7","author":"F Li","year":"2017","unstructured":"Li F, Miao L, et al. Establishment of a new acute-on-chronic liver failure model. Acta Pharm Sin B. 2017;7(3):326\u201333.","journal-title":"Acta Pharm Sin B"},{"issue":"8","key":"3696_CR70","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1046\/j.1365-2036.2002.01314.x","volume":"16","author":"P Pazzi","year":"2002","unstructured":"Pazzi P, Morsiani E, et al. Serum bile acids in patients with liver failure supported with a bioartificial liver. Aliment Pharmacol Ther. 2002;16(8):1547\u201354.","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"3696_CR71","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1136\/gutjnl-2017-315259","volume":"67","author":"GM Hirschfield","year":"2018","unstructured":"Hirschfield GM, Dyson JK, et al. The British Society of Gastroenterology\/UK-PBC primary biliary cholangitis treatment and management guidelines. Gut. 2018;67(9):1568\u201394.","journal-title":"Gut"},{"issue":"2","key":"3696_CR72","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.jhep.2019.04.001","volume":"71","author":"MH Harms","year":"2019","unstructured":"Harms MH, van Buuren HR, et al. Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2019;71(2):357\u201365.","journal-title":"J Hepatol"},{"issue":"4","key":"3696_CR73","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1016\/j.jhep.2024.05.010","volume":"81","author":"AJ Montano-Loza","year":"2024","unstructured":"Montano-Loza AJ, Lytvyak E, et al. Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation. J Hepatol. 2024;81(4):679\u201389.","journal-title":"J Hepatol"},{"key":"3696_CR74","first-page":"7831165","volume":"2022","author":"M Mijic","year":"2022","unstructured":"Mijic M, Saric I, et al. Pretransplant evaluation and liver transplantation outcome in PBC patients. Can J Gastroenterol Hepatol. 2022;2022:7831165.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"8","key":"3696_CR75","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1111\/apt.17908","volume":"59","author":"BS Hofer","year":"2024","unstructured":"Hofer BS, Burghart L, et al. Evaluation of potential hepatic recompensation criteria in patients with PBC and decompensated cirrhosis. Aliment Pharmacol Ther. 2024;59(8):962\u201372.","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"3696_CR76","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v17.i8.108606","volume":"17","author":"E Zerem","year":"2025","unstructured":"Zerem E, Kunosic S, et al. Bile acids in metabolic dysfunction-associated steatotic liver disease. World J Hepatol. 2025;17(8):108606.","journal-title":"World J Hepatol"},{"issue":"7","key":"3696_CR77","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.metabol.2011.10.023","volume":"61","author":"T Tsuchida","year":"2012","unstructured":"Tsuchida T, Shiraishi M, et al. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice. Metabolism. 2012;61(7):944\u201353.","journal-title":"Metabolism"},{"issue":"5","key":"3696_CR78","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1002\/hep.25531","volume":"55","author":"A Pathil","year":"2012","unstructured":"Pathil A, Mueller J, et al. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease. Hepatology. 2012;55(5):1369\u201378.","journal-title":"Hepatology"},{"issue":"6","key":"3696_CR79","first-page":"1464","volume":"23","author":"J Laurin","year":"1996","unstructured":"Laurin J, Lindor KD, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology. 1996;23(6):1464\u20137.","journal-title":"Hepatology"},{"issue":"12","key":"3696_CR80","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.cgh.2006.09.025","volume":"4","author":"JF Dufour","year":"2006","unstructured":"Dufour JF, Oneta CM, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006;4(12):1537\u201343.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"3696_CR81","first-page":"1247","volume":"24","author":"SD Wu","year":"2012","unstructured":"Wu SD, Li L, et al. Ursodeoxycholic acid for nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2012;24(11):1247\u201353.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3696_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10102464","author":"A Floreani","year":"2022","unstructured":"Floreani A, Gabbia D, et al. Obeticholic acid for primary biliary cholangitis. Biomedicines. 2022. https:\/\/doi.org\/10.3390\/biomedicines10102464.","journal-title":"Biomedicines"},{"issue":"4","key":"3696_CR83","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/apt.16181","volume":"53","author":"E Gomez","year":"2021","unstructured":"Gomez E, Garcia Buey L, et al. Effectiveness and safety of obeticholic acid in a southern European multicentre cohort of patients with primary biliary cholangitis and suboptimal response to ursodeoxycholic acid. Aliment Pharmacol Ther. 2021;53(4):519\u201330.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"3696_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100248","volume":"3","author":"D D'Amato","year":"2021","unstructured":"D\u2019Amato D, De Vincentis A, et al. Real-world experience with obeticholic acid in patients with primary biliary cholangitis. JHEP Rep. 2021;3(2):100248.","journal-title":"JHEP Rep"},{"issue":"9","key":"3696_CR85","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/hep4.1518","volume":"4","author":"SB Roberts","year":"2020","unstructured":"Roberts SB, Ismail M, et al. Real-world effectiveness of obeticholic acid in patients with primary biliary cholangitis. Hepatol Commun. 2020;4(9):1332\u201345.","journal-title":"Hepatol Commun"},{"issue":"9972","key":"3696_CR86","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","volume":"385","author":"BA Neuschwander-Tetri","year":"2015","unstructured":"Neuschwander-Tetri BA, Loomba R, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet. 2015;385(9972):956\u201365.","journal-title":"Lancet"},{"issue":"10215","key":"3696_CR87","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","volume":"394","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Ratziu V, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394(10215):2184\u201396.","journal-title":"Lancet"},{"issue":"3","key":"3696_CR88","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jhep.2021.10.029","volume":"76","author":"ME Rinella","year":"2022","unstructured":"Rinella ME, Dufour JF, et al. Non-invasive evaluation of response to obeticholic acid in patients with NASH: results from the REGENERATE study. J Hepatol. 2022;76(3):536\u201348.","journal-title":"J Hepatol"},{"issue":"8","key":"3696_CR89","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1002\/hep4.1720","volume":"5","author":"BV John","year":"2021","unstructured":"John BV, Schwartz K, et al. Impact of obeticholic acid exposure on decompensation and mortality in primary biliary cholangitis and cirrhosis. Hepatol Commun. 2021;5(8):1426\u201336.","journal-title":"Hepatol Commun"},{"issue":"3","key":"3696_CR90","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000454904","volume":"35","author":"E Halilbasic","year":"2017","unstructured":"Halilbasic E, Steinacher D, et al. Nor-ursodeoxycholic acid as a novel therapeutic approach for cholestatic and metabolic liver diseases. Dig Dis. 2017;35(3):288\u201392.","journal-title":"Dig Dis"},{"issue":"5","key":"3696_CR91","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1002\/hep.23911","volume":"52","author":"GU Denk","year":"2010","unstructured":"Denk GU, Maitz S, et al. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver. Hepatology. 2010;52(5):1758\u201368.","journal-title":"Hepatology"},{"issue":"6","key":"3696_CR92","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.jhep.2013.01.026","volume":"58","author":"P Fickert","year":"2013","unstructured":"Fickert P, Pollheimer MJ, et al. Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. J Hepatol. 2013;58(6):1201\u20138.","journal-title":"J Hepatol"},{"issue":"3","key":"3696_CR93","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.jhep.2017.05.009","volume":"67","author":"P Fickert","year":"2017","unstructured":"Fickert P, Hirschfield GM, et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J Hepatol. 2017;67(3):549\u201358.","journal-title":"J Hepatol"},{"issue":"11","key":"3696_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100872","volume":"5","author":"C Grander","year":"2023","unstructured":"Grander C, Meyer M, et al. 24-Norursodeoxycholic acid ameliorates experimental alcohol-related liver disease and activates hepatic PPAR\u03b3. JHEP Reports. 2023;5(11):100872.","journal-title":"JHEP Reports"},{"issue":"3","key":"3696_CR95","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/hep.30509","volume":"70","author":"M Trauner","year":"2019","unstructured":"Trauner M, Gulamhusein A, et al. The nonsteroidal farnesoid X receptor agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with primary sclerosing cholangitis. Hepatology. 2019;70(3):788\u2013801.","journal-title":"Hepatology"},{"issue":"6","key":"3696_CR96","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.cgh.2022.07.024","volume":"21","author":"M Trauner","year":"2023","unstructured":"Trauner M, Bowlus CL, et al. Safety and sustained efficacy of the farnesoid X receptor (FXR) agonist cilofexor over a 96-week open-label extension in patients with PSC. Clin Gastroenterol Hepatol. 2023;21(6):1552-60.e2.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"3696_CR97","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000744","volume":"15","author":"C Levy","year":"2024","unstructured":"Levy C, Caldwell S, et al. Cilofexor in patients with compensated cirrhosis due to primary sclerosing cholangitis: an open-label phase 1B study. Clin Transl Gastroenterol. 2024;15(8):e00744.","journal-title":"Clin Transl Gastroenterol"},{"issue":"1","key":"3696_CR98","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S2468-1253(25)00208-0","volume":"11","author":"M Trauner","year":"2026","unstructured":"Trauner M, Levy C, et al. Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(1):46\u201358.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"3696_CR99","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","volume":"77","author":"N Alkhouri","year":"2022","unstructured":"Alkhouri N, Herring R, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial. J Hepatol. 2022;77(3):607\u201318.","journal-title":"J Hepatol"},{"issue":"1","key":"3696_CR100","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/hep.31205","volume":"72","author":"K Patel","year":"2020","unstructured":"Patel K, Harrison SA, et al. Cilofexor, a nonsteroidal FXR agonist, in patients with noncirrhotic NASH: a phase 2 randomized controlled trial. Hepatology. 2020;72(1):58\u201371.","journal-title":"Hepatology"},{"issue":"5","key":"3696_CR101","doi-asserted-by":"publisher","first-page":"759","DOI":"10.21037\/hbsn-23-342","volume":"12","author":"M Yoneda","year":"2023","unstructured":"Yoneda M, Kobayashi T, et al. Tropifexor, a selective non-acid farnesoid X receptor agonist, improved nonalcoholic steatohepatitis in a phase 2 trial, but several issues remain to be resolved. Hepatobiliary Surg Nutr. 2023;12(5):759\u201362.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"2","key":"3696_CR102","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-022-02200-8","volume":"29","author":"AJ Sanyal","year":"2023","unstructured":"Sanyal AJ, Lopez P, et al. Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a\/b trial. Nat Med. 2023;29(2):392\u2013400.","journal-title":"Nat Med"},{"issue":"4","key":"3696_CR103","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1097\/HEP.0000000000000439","volume":"78","author":"QM Anstee","year":"2023","unstructured":"Anstee QM, Lucas KJ, et al. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study. Hepatology. 2023;78(4):1223\u201339.","journal-title":"Hepatology"},{"issue":"2","key":"3696_CR104","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/med.21991","volume":"44","author":"K Wang","year":"2024","unstructured":"Wang K, Zhang Y, et al. FXR agonists for MASH therapy: lessons and perspectives from obeticholic acid. Med Res Rev. 2024;44(2):568\u201386.","journal-title":"Med Res Rev"},{"key":"3696_CR105","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3389\/fphar.2018.00931","volume":"9","author":"S Al-Dury","year":"2018","unstructured":"Al-Dury S, Marschall HU. Ileal bile acid transporter inhibition for the treatment of chronic constipation, cholestatic pruritus, and NASH. Front Pharmacol. 2018;9:931.","journal-title":"Front Pharmacol"},{"issue":"5","key":"3696_CR106","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1007\/s12072-020-10070-w","volume":"14","author":"SJ Karpen","year":"2020","unstructured":"Karpen SJ, Kelly D, et al. Ileal bile acid transporter inhibition as an anticholestatic therapeutic target in biliary atresia and other cholestatic disorders. Hepatol Int. 2020;14(5):677\u201389.","journal-title":"Hepatol Int"},{"issue":"9","key":"3696_CR107","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","volume":"7","author":"RJ Thompson","year":"2022","unstructured":"Thompson RJ, Arnell H, et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2022;7(9):830\u201342.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"3696_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100782","volume":"5","author":"RJ Thompson","year":"2023","unstructured":"Thompson RJ, Artan R, et al. Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis. JHEP Rep. 2023;5(8):100782.","journal-title":"JHEP Rep"},{"issue":"4","key":"3696_CR109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2024.101309","volume":"7","author":"A Di Giorgio","year":"2025","unstructured":"Di Giorgio A, Sciveres M, et al. Real-world experience with odevixibat in children with progressive familial intrahepatic cholestasis. JHEP Rep. 2025;7(4):101309.","journal-title":"JHEP Rep"},{"issue":"7","key":"3696_CR110","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S2468-1253(24)00074-8","volume":"9","author":"N Ovchinsky","year":"2024","unstructured":"Ovchinsky N, Aumar M, et al. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2024;9(7):632\u201345.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"3696_CR111","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1038\/s41598-018-25214-0","volume":"8","author":"S Al-Dury","year":"2018","unstructured":"Al-Dury S, Wahlstr\u00f6m A, et al. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis. Sci Rep. 2018;8(1):6658.","journal-title":"Sci Rep"},{"issue":"1","key":"3696_CR112","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2468-1253(25)00192-X","volume":"11","author":"GM Hirschfield","year":"2026","unstructured":"Hirschfield GM, Bowlus CL, et al. Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026;11(1):22\u201333.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"3696_CR113","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1016\/j.cgh.2022.10.032","volume":"21","author":"C Levy","year":"2023","unstructured":"Levy C, Kendrick S, et al. GLIMMER: a randomized phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus. Clin Gastroenterol Hepatol. 2023;21(7):1902-12.e13.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"3696_CR114","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1111\/liv.15982","volume":"44","author":"E Karatza","year":"2024","unstructured":"Karatza E, Swift B, et al. Serum bile acid change correlates with improvement in pruritus in patients with primary biliary cholangitis receiving linerixibat. Liver Int. 2024;44(9):2293\u2013302.","journal-title":"Liver Int"},{"issue":"7","key":"3696_CR115","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S2468-1253(24)00080-3","volume":"9","author":"AG Miethke","year":"2024","unstructured":"Miethke AG, Moukarzel A, et al. Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2024;9(7):620\u201331.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"10311","key":"3696_CR116","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","volume":"398","author":"E Gonzales","year":"2021","unstructured":"Gonzales E, Hardikar W, et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet. 2021;398(10311):1581\u201392.","journal-title":"Lancet"},{"issue":"6","key":"3696_CR117","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1097\/HEP.0000000000000502","volume":"78","author":"RJ Sokol","year":"2023","unstructured":"Sokol RJ, Gonzales EM, et al. Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor. Hepatology. 2023;78(6):1698\u2013710.","journal-title":"Hepatology"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03696-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03696-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03696-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:02:56Z","timestamp":1794254576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03696-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":117,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["3696"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03696-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"28 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Guangwen Cao, Haonan Zhao, Guo Lin, Junxiu Chen, Cong Gao, Nahum M\u00e9ndez-S\u00e1nchez, and Fei Gao have nothing to disclose. Xingshun Qi is an editorial board member of Advances in Therapy. Xingshun Qi was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This is a review article based on previously conducted studies, and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}